• 亿邦公众号
    • APP下载

京东健康Q3财报:营收破200亿元增16.9% 日均AI健康服务交互量同比增长超5倍

作者:亿邦动力 文章来源:亿邦动力

2026-11-18 14:28

作者:亿邦动力 文章来源:亿邦动力

2026-11-18 14:28

邦小白快读

EN
全文速览

总1:先看京东健康2026年第三季度财报核心数据。

1.营收200.17亿元,同比增长16.9%。

2.经营盈利11.95亿元,同比下降3.9%;非国际财务报告准则经营盈利15.75亿元,同比增长14.3%。

3.期内盈利15.57亿元,同比下降15.3%;非国际财务报告准则盈利19.31亿元,同比增长1.5%。

总2:再看与日常买药、用药服务相关的实操信息。

1.截至2026年9月30日,累计超110家药企选择京东健康作为新品首发合作伙伴,第三季度超50款新药首发上线,包括扬子江药业百乐眠、金赛药业金蓓欣、恒瑞医药恒宜等。

2.买药秒送夜间购药服务已拓展至全国超300个城市,多个城市升级冷链配送,可实现上百种药品全程温控配送和实时监测。

3.AI医生大为服务用户规模快速增长,日均AI健康服务交互量同比增长超5倍。

总1:新品首发是品牌营销和渠道建设的重要抓手。

1.截至2026年9月30日,累计超110家药企选择京东健康作为新品首发合作伙伴,说明平台已形成药企新品首发合作基础。

2.第三季度超50款新药通过京东健康首发上线,代表案例包括扬子江药业百乐眠、金赛药业金蓓欣、恒瑞医药恒宜。

3.公司与利奥制药、云顶新耀、立康生命科技等深化合作,围绕AI赋能的专科患者服务及慢病全病程管理探索创新服务模式。

总2:履约网络和AI服务影响用户触达与用药体验。

1.买药秒送夜间购药服务拓展至全国超300个城市,有助于扩大夜间购药场景覆盖。

2.多个城市升级冷链配送,可实现上百种药品全程温控配送和实时监测,增强药品渠道履约能力。

3.AI医生大为日均AI健康服务交互量同比增长超5倍,反映用户对AI健康服务存在增长需求。

总1:增长市场和合作机会集中在药品首发、即时履约与AI健康服务。

1.累计超110家药企选择京东健康作为新品首发合作伙伴,第三季度超50款新药首发上线,卖家可关注新品首发合作方式。

2.买药秒送夜间购药服务拓展至全国超300个城市,夜间购药是消费需求变化带来的增量场景。

3.多个城市升级冷链配送,可实现上百种药品全程温控配送和实时监测,为药品履约提供机会。

总2:AI服务和慢病管理是可学习的合作方向,同时需注意盈利指标分化。

1.公司与利奥制药、云顶新耀、立康生命科技等围绕AI赋能的专科患者服务及慢病全病程管理深化合作,卖家可关注专科服务和慢病管理合作模式。

2.AI医生大为日均AI健康服务交互量同比增长超5倍,说明AI健康服务交互需求增长。

3.财报显示营收同比增长16.9%,但经营盈利同比下降3.9%、期内盈利同比下降15.3%,需关注增长与盈利压力并存的风险。

总1:药品首发和冷链履约带来产品生产与设计需求。

1.第三季度超50款新药通过京东健康首发上线,累计超110家药企选择京东健康作为新品首发合作伙伴,说明新药上市和首发合作存在商业机会。

2.买药秒送在多个城市升级冷链配送服务,可实现上百种药品全程温控配送和实时监测,工厂可关注药品冷链包装、温控能力和实时监测需求。

3.夜间购药服务拓展至全国超300个城市,反映夜间药品供应和履约场景扩展。

总2:数字化和电商启示体现在AI健康服务与全病程管理。

1.公司与药企围绕AI赋能的专科患者服务及慢病全病程管理探索创新服务模式,提示工厂可关注药品与患者服务、慢病管理的衔接。

2.AI医生大为日均AI健康服务交互量同比增长超5倍,说明AI健康服务交互增长,对数字化服务能力提出新要求。

3.冷链配送的全程温控和实时监测,体现药品履约数字化、可追溯化方向。

总1:行业趋势显示AI健康服务与即时药品履约正在扩展。

1.AI医生大为日均AI健康服务交互量同比增长超5倍,AI健康服务交互需求快速增长。

2.公司与利奥制药、云顶新耀、立康生命科技等围绕AI赋能的专科患者服务及慢病全病程管理探索创新服务模式。

3.买药秒送夜间购药服务拓展至全国超300个城市,多个城市升级冷链配送,可实现上百种药品全程温控配送和实时监测。

总2:客户痛点和解决方案集中在夜间购药、冷链温控和慢病管理。

1.夜间购药服务覆盖超300个城市,对应夜间用药可及性需求。

2.冷链配送支持上百种药品全程温控和实时监测,对应药品温控与质量保障痛点。

3.药企新品首发累计超110家、第三季度超50款新药首发,且AI专科患者服务和慢病全病程管理成为合作方向,服务商可关注首发服务、患者服务和慢病管理解决方案。

总1:平台最新做法集中在药企新品首发、AI健康服务和即时履约。

1.截至2026年9月30日,累计超110家药企选择京东健康作为新品首发合作伙伴,第三季度超50款新药首发上线,平台招商可关注药企新品首发合作。

2.公司与利奥制药、云顶新耀、立康生命科技等深化合作,围绕AI赋能的专科患者服务及慢病全病程管理探索创新服务模式。

3.买药秒送夜间购药服务拓展至全国超300个城市,多个城市升级冷链配送,可实现上百种药品全程温控配送和实时监测。

总2:运营管理和风向规避需关注AI交互增长与盈利指标分化。

1.AI医生大为日均AI健康服务交互量同比增长超5倍,平台运营需关注AI健康服务交互能力和用户服务承接。

2.营收200.17亿元,同比增长16.9%;非国际财务报告准则经营盈利15.75亿元,同比增长14.3%,显示收入和非国际准则经营盈利增长。

3.经营盈利11.95亿元,同比下降3.9%;期内盈利15.57亿元,同比下降15.3%,平台需关注增长与盈利压力并存。

总1:产业新动向是医药电商平台向新品首发、AI患者服务和慢病全病程管理延伸。

1.截至2026年9月30日,累计超110家药企选择京东健康作为新品首发合作伙伴,第三季度超50款新药通过京东健康首发上线,代表药企包括扬子江药业、金赛药业、恒瑞医药。

2.公司与利奥制药、云顶新耀、立康生命科技等围绕AI赋能的专科患者服务及慢病全病程管理探索创新服务模式,提升药品可及性与患者用药体验。

3.AI医生大为日均AI健康服务交互量同比增长超5倍,显示AI健康服务规模化交互趋势。

总2:新问题与商业模式观察包括即时履约扩展和盈利指标分化。

1.买药秒送夜间购药服务拓展至全国超300个城市,多个城市升级冷链配送,可实现上百种药品全程温控配送和实时监测,体现药品即时零售和冷链可及性发展。

2.营收200.17亿元,同比增长16.9%;经营盈利11.95亿元,同比下降3.9%;期内盈利15.57亿元,同比下降15.3%;非国际财务报告准则盈利19.31亿元,同比增长1.5%,呈现收入增长与部分盈利指标下降并存。

3.商业模式可归纳为药企新品首发合作、AI专科患者服务、慢病全病程管理和即时履约服务相结合。

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Summary 1: Start with the core data from JD Health's Q3 2026 financial report.

1. Revenue was RMB20.017 billion, up 16.9% year over year.

2. Operating profit was RMB1.195 billion, down 3.9% year over year; non-IFRS operating profit was RMB1.575 billion, up 14.3% year over year.

3. Profit for the period was RMB1.557 billion, down 15.3% year over year; non-IFRS profit was RMB1.931 billion, up 1.5% year over year.

Summary 2: Practical information related to daily medicine purchases and medication services.

1. As of September 30, 2026, more than 110 pharmaceutical companies had chosen JD Health as a new-product launch partner. In Q3, more than 50 new drugs debuted on the platform, including Yangzijiang Pharmaceutical's Bailemian, Jinsai Pharmaceutical's Jinbeixin, and Hengrui Pharma's Hengyi.

2. The Buy Medicine in Seconds nighttime medicine purchase service has expanded to more than 300 cities nationwide. Multiple cities have upgraded cold-chain delivery, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process.

3. The user base for the AI doctor Dawei service grew rapidly, with average daily AI health service interactions increasing more than fivefold year over year.

Summary 1: New-product launches are an important lever for brand marketing and channel building.

1. As of September 30, 2026, more than 110 pharmaceutical companies had chosen JD Health as a new-product launch partner, indicating that the platform has established a foundation for pharmaceutical new-product launch cooperation.

2. In Q3, more than 50 new drugs were launched through JD Health, with representative cases including Yangzijiang Pharmaceutical's Bailemian, Jinsai Pharmaceutical's Jinbeixin, and Hengrui Pharma's Hengyi.

3. The company deepened cooperation with Leo Pharma, Everest Medicines, Likang Life Sciences, and others to explore innovative service models around AI-enabled specialty patient services and whole-course chronic disease management.

Summary 2: Fulfillment networks and AI services affect user reach and medication experience.

1. Buy Medicine in Seconds nighttime medicine purchase services expanded to more than 300 cities nationwide, helping broaden coverage of nighttime medicine purchase scenarios.

2. Multiple cities upgraded cold-chain delivery, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process, strengthening the channel fulfillment capability for medicines.

3. Average daily AI health service interactions for the AI doctor Dawei increased more than fivefold year over year, reflecting growing user demand for AI health services.

Summary 1: Growth markets and partnership opportunities are concentrated in new drug launches, instant fulfillment, and AI health services.

1. More than 110 pharmaceutical companies have chosen JD Health as a new-product launch partner, and more than 50 new drugs launched in Q3. Sellers can monitor new-product launch cooperation models.

2. Buy Medicine in Seconds nighttime medicine purchase services expanded to more than 300 cities nationwide. Nighttime medicine purchases represent an incremental scenario driven by changes in consumer demand.

3. Multiple cities upgraded cold-chain delivery, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process, creating opportunities in medicine fulfillment.

Summary 2: AI services and chronic disease management are partnership directions to learn from, while divergent profit indicators require attention.

1. The company deepened cooperation with Leo Pharma, Everest Medicines, Likang Life Sciences, and others around AI-enabled specialty patient services and whole-course chronic disease management. Sellers can monitor specialty-service and chronic disease management cooperation models.

2. Average daily AI health service interactions for the AI doctor Dawei increased more than fivefold year over year, indicating growth in demand for AI health service interactions.

3. The financial report shows revenue up 16.9% year over year, but operating profit down 3.9% and profit for the period down 15.3%. Sellers should note the coexistence of growth and profit pressure.

Summary 1: New drug launches and cold-chain fulfillment create product production and design needs.

1. In Q3, more than 50 new drugs were launched through JD Health, and more than 110 pharmaceutical companies had chosen JD Health as a new-product launch partner, indicating commercial opportunities in new drug launches and launch cooperation.

2. Buy Medicine in Seconds upgraded cold-chain delivery services in multiple cities, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process. Factories can monitor demand for cold-chain packaging, temperature-control capabilities, and real-time monitoring.

3. Nighttime medicine purchase services expanded to more than 300 cities nationwide, reflecting the expansion of nighttime medicine supply and fulfillment scenarios.

Summary 2: Digitalization and e-commerce insights are reflected in AI health services and whole-course management.

1. The company is exploring innovative service models with pharmaceutical companies around AI-enabled specialty patient services and whole-course chronic disease management, suggesting that factories can monitor links between medicines, patient services, and chronic disease management.

2. Average daily AI health service interactions for the AI doctor Dawei increased more than fivefold year over year, indicating growth in AI health service interactions and new requirements for digital service capabilities.

3. End-to-end temperature control and real-time monitoring in cold-chain delivery reflect the direction of digitalization and traceability in medicine fulfillment.

Summary 1: Industry trends show that AI health services and instant medicine fulfillment are expanding.

1. Average daily AI health service interactions for the AI doctor Dawei increased more than fivefold year over year, indicating rapid growth in demand for AI health service interactions.

2. The company is exploring innovative service models with Leo Pharma, Everest Medicines, Likang Life Sciences, and others around AI-enabled specialty patient services and whole-course chronic disease management.

3. Buy Medicine in Seconds nighttime medicine purchase services expanded to more than 300 cities nationwide, and multiple cities upgraded cold-chain delivery, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process.

Summary 2: Customer pain points and solutions are concentrated in nighttime medicine purchases, cold-chain temperature control, and chronic disease management.

1. Nighttime medicine purchase services cover more than 300 cities, corresponding to demand for nighttime medication accessibility.

2. Cold-chain delivery supports end-to-end temperature control and real-time monitoring for more than 100 types of medicines, corresponding to pain points in medicine temperature control and quality assurance.

3. More than 110 pharmaceutical companies have participated in new-product launches, with more than 50 new drugs launched in Q3, and AI specialty patient services and whole-course chronic disease management have become cooperation directions. Service providers can focus on launch services, patient services, and chronic disease management solutions.

Summary 1: The platform's latest moves focus on pharmaceutical new-product launches, AI health services, and instant fulfillment.

1. As of September 30, 2026, more than 110 pharmaceutical companies had chosen JD Health as a new-product launch partner, and more than 50 new drugs launched in Q3. Platform merchant recruitment can focus on pharmaceutical new-product launch cooperation.

2. The company deepened cooperation with Leo Pharma, Everest Medicines, Likang Life Sciences, and others to explore innovative service models around AI-enabled specialty patient services and whole-course chronic disease management.

3. Buy Medicine in Seconds nighttime medicine purchase services expanded to more than 300 cities nationwide, and multiple cities upgraded cold-chain delivery, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process.

Summary 2: Operational management and risk avoidance should focus on AI interaction growth and divergent profit indicators.

1. Average daily AI health service interactions for the AI doctor Dawei increased more than fivefold year over year. Platform operations need to focus on AI health service interaction capabilities and user service capacity.

2. Revenue was RMB20.017 billion, up 16.9% year over year; non-IFRS operating profit was RMB1.575 billion, up 14.3% year over year, showing growth in revenue and non-IFRS operating profit.

3. Operating profit was RMB1.195 billion, down 3.9% year over year; profit for the period was RMB1.557 billion, down 15.3% year over year. The platform needs to monitor the coexistence of growth and profit pressure.

Summary 1: A new industry development is the extension of pharmaceutical e-commerce platforms into new-product launches, AI patient services, and whole-course chronic disease management.

1. As of September 30, 2026, more than 110 pharmaceutical companies had chosen JD Health as a new-product launch partner, and more than 50 new drugs were launched through JD Health in Q3. Representative pharmaceutical companies include Yangzijiang Pharmaceutical, Jinsai Pharmaceutical, and Hengrui Pharma.

2. The company is exploring innovative service models with Leo Pharma, Everest Medicines, Likang Life Sciences, and others around AI-enabled specialty patient services and whole-course chronic disease management, improving medicine accessibility and patient medication experience.

3. Average daily AI health service interactions for the AI doctor Dawei increased more than fivefold year over year, showing a trend toward scaled AI health service interactions.

Summary 2: New issues and business model observations include instant fulfillment expansion and divergent profit indicators.

1. Buy Medicine in Seconds nighttime medicine purchase services expanded to more than 300 cities nationwide, and multiple cities upgraded cold-chain delivery, enabling temperature-controlled delivery and real-time monitoring for more than 100 types of medicines throughout the process, reflecting the development of instant retail and cold-chain accessibility for medicines.

2. Revenue was RMB20.017 billion, up 16.9% year over year; operating profit was RMB1.195 billion, down 3.9% year over year; profit for the period was RMB1.557 billion, down 15.3% year over year; non-IFRS profit was RMB1.931 billion, up 1.5% year over year, presenting revenue growth alongside declines in some profit indicators.

3. The business model can be summarized as a combination of pharmaceutical new-product launch cooperation, AI specialty patient services, whole-course chronic disease management, and instant fulfillment services.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】11月17日,京东健康发布公告,2026年第三季度实现收入200.17亿元,同比增长16.9%;经营盈利11.95亿元,同比下降3.9%;非国际财务报告准则经营盈利15.75亿元,同比增长14.3%;期内盈利15.57亿元,同比下降15.3%;非国际财务报告准则盈利19.31亿元,同比增长1.5%。

公告提到,截至2026年9月30日,累计超110家药企选择京东健康作为新品首发合作伙伴。第三季度,扬子江药业创新药百乐眠®、金赛药业国产痛风创新药金蓓欣®、恒瑞医药新药恒宜®等超50款新药通过京东健康首发上线。在药企合作方面,公司与利奥制药、云顶新耀、立康生命科技等合作伙伴深化合作,围绕AI赋能的专科患者服务及慢病全病程管理,共同探索创新服务模式,提升药品可及性与患者用药体验。

2026年第三季度,京东健康买药秒送履约服务已将夜间购药服务拓展至全国超300个城市。同时,京东买药秒送在多个城市升级现有冷链配送服务,可实现上百种药品的全程温控配送和实时监测。

2026年第三季度,AI医生“大为”服务用户规模保持快速增长,日均AI健康服务交互量同比增长超5倍。


本文首发于 亿邦动力 官方网站

【版权提示】亿邦动力倡导尊重与保护知识产权。未经许可,任何人不得复制、转载、或以其他方式使用本网站的内容。如发现本站文章存在版权问题,烦请提供版权疑问、身份证明、版权证明、联系方式等发邮件至run@ebrun.com,我们将及时沟通与处理。

已点赞

+1

{{ praise_text }}

好文章,值得被更多人看到

FAQ回顾

京东健康2026年第三季度业绩表现如何?

2026年第三季度京东健康实现收入200.17亿元,同比增长16.9%;经营盈利11.95亿元,同比下降3.9%;非国际财务报告准则经营盈利15.75亿元,同比增长14.3%;期内盈利15.57亿元,同比下降15.3%;非国际财务报告准则盈利19.31亿元,同比增长1.5%。

京东健康在AI医疗健康服务方面有哪些进展?

2026年第三季度,AI医生“大为”服务用户规模保持快速增长,日均AI健康服务交互量同比增长超5倍。京东健康还与药企围绕AI赋能的专科患者服务及慢病全病程管理探索创新服务模式。

药企为什么选择京东健康作为新品首发平台?

截至2026年9月30日,累计超110家药企选择京东健康作为新品首发合作伙伴。第三季度,扬子江药业百乐眠®、金赛药业金蓓欣®、恒瑞医药恒宜®等超50款新药通过京东健康首发上线。

京东健康买药秒送在夜间购药和冷链配送方面覆盖如何?

2026年第三季度,京东健康买药秒送履约服务已将夜间购药服务拓展至全国超300个城市。同时,京东买药秒送在多个城市升级冷链配送服务,可实现上百种药品的全程温控配送和实时监测。

京东健康与药企合作探索哪些创新服务模式?

京东健康与利奥制药、云顶新耀、立康生命科技等合作伙伴深化合作,围绕AI赋能的专科患者服务及慢病全病程管理,共同探索创新服务模式,提升药品可及性与患者用药体验。

广告

下一篇

征集报名《品牌数字化服务商资源手册》

《品牌数字化服务商资源手册》展示数字化服务商风采,亿邦全年零售大会通发,触达更多资源,马上加入!

马上入驻

千峰访谈兰格云商刘陶然:从“线上工具化”走向“产业生态化”

本届千峰奖访谈中,刘陶然围绕AI与出海带来的模态进化,分享了兰格云商在钢铁产业互联网方向的实践与判断。